Fulcrum Pharma - drug development to regulatory approval (1.1.07)

Intro: Fulcrum Pharma is a drug development and regulatory services business - operating mainly in Europe, USA and Japan - which provides global expertise to achieve drug development and regulatory approval milestones. On offer is immediate access to a highly credible and integrated development team that provides the strategic and operational leadership required to ensure new drugs move smoothly from discovery research through to product approval.

Charts

Long Term Chart

Fundamental Data

Sector   PHARMACEUTICALS & BIOTECHNOLOGY   Mkt.Sector   AIM   Mkt.Segment   AIM   Turnover   16.76   Profit   -0.17   Norm EPS   -0.33   PE Ratio   -   Market cap   6.90   NMS   -

News

19/11/09 11:12 UKREG 12/11/09 07:00 UKREG

Frequent collaboration and sharing of skill sets amongst Fulcrum's European, US and Japanese operations allows the company to operate in three of the most significant sectors of the pharmaceutical industry. This means they can design, manage and execute drug development projects globally and provide expertise and resources for regulatory submissions and health authority meetings in all three regions. In this way, Fulcrum provides its clients with integrated services covering a world-wide area. Last year's shrewd purchase of Quadramed Ltd signified their intentions to expand not just organically but also by acquisition.

Website:

Results diary (year end 31 August):

'Interim' 2009 [announced 14 May] -
T/over - £8.246m; Profit (net) - £0.122m; eps - 0.07p

'Final' 2008 [announced 12 November] -
T/over - £14.826m; Profit (net) - £0.324m; eps - 0.19p

'Interim' 2008 [announced 22 May] -
T/over - £7.444m; Profit (net) - £0.066m; eps - 0.04p

'Final' 2007 [announced 26 November] -
T/over - £11.503m; Profit (net) - £0.141m; eps - 0.10p

'Interim' 2007 [announced 17 May] -
T/over - £4.859m; Profit (net) - £0.108m; eps - 0.07p

'Final' 2006 [announced 9 Nov] -
T/over - £15.491m; Profit (net) - £0.142m; eps - 0.12p
[

Shares in issue: 177,940,743

Directors (shareholding): [totaling 11,114,563 or 6.25%]

Dr F Armstrong (850,000)[Chair]
Dr J A Devlin (7,093,975)
B Knight (100,000)[FD]
# G Cook (1,600,000)
# Dr J A Bell (970,588)
# Dr M G Carter (Nil)
# F Condella (250.000)
# K Lacey (250,000)
[# denotes non-exec]

Substantial interests: [totaling 111,033,080 or 62.4%]

Bluehone Investors LLP - 25,117,986 (14.1%)
Pershing Nominees Ltd - 9,558,940 (5.4%)
HSBC Global Custody Nominee Ltd - 9,233,065 (5.2%)
Dr J P Court - 7,461,622 (4.2%)
Pinnacle Trustees Ltd - 7,215,686 (4.1%)
Dr J A Devlin - 7,093,975 (4.0%)
N G Oughton - 6,976,328 (3.9%)
Dr G E Walters - 6,976,328 (3.9%)
Rathbone Nominees Ltd - 6,653,415 (3.7%)
Dr R M Miller - 6,476,328 (3.6%)
Barclayshare Nominees Ltd - 6,414,940 (3.6%)
Giltspur Nominees Ltd - 6,073,332 (3.4%)
T D Waterhouse Nominees (Eur) 5,781,135 (3.2%)